Abstract
The article presents a clinical case of treatment of orbital B-cell lymphoma of the extranodal marginal zone. This case report demonstrates the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory LMZ previously reported in the PCYC-1121 study. Research and clinical evidence support the use of ibrutinib monotherapy as an alternative to chemotherapy in this patient population with a favorable benefit-risk profile and a convenient once-daily regimen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
